2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2023
Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis
Hagler M, Ferrara M, Yoviene Sykes L, Li F, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Mathalon D, Seidman L, Tsuang M, Walker E, Powers A, Allen A, Srihari V, Woods S. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis. Schizophrenia Research 2023, 255: 239-245. PMID: 37028205, PMCID: PMC10207144, DOI: 10.1016/j.schres.2023.03.047.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesClinical high riskClinical high-risk individualsEarly detectionFirst-episode psychosis individualsRecent psychiatric hospitalizationCourse of illnessHigh-risk individualsAttenuated positive symptomsCHR researchGeographic catchmentSyndromal psychosisPsychosis individualsPsychiatric hospitalizationEarly intervention effortsHigh riskPsychosis servicesPositive symptomsGlobal functioningClinical resourcesProtective factorsDifferent populationsFE participantsGeneralizability of findingsFES programSelf-reported Gesture Interpretation and Performance Deficits in Individuals at Clinical High Risk for Psychosis
Karp E, Williams T, Ellman L, Strauss G, Walker E, Corlett P, Woods S, Powers A, Gold J, Schiffman J, Waltz J, Silverstein S, Mittal V. Self-reported Gesture Interpretation and Performance Deficits in Individuals at Clinical High Risk for Psychosis. Schizophrenia Bulletin 2023, 49: 746-755. PMID: 36939086, PMCID: PMC10154698, DOI: 10.1093/schbul/sbac197.Peer-Reviewed Original ResearchConceptsClinical high riskGesture deficitsInternalizing disordersCHR groupGesture interpretationLower verbal learningViable assessment toolVerbal learningNeurocognitive tasksGeneral intelligencePerformance deficitsNonverbal behaviorProcessing speedCHR participantsSimilar deficitsGreater deficitsHigh riskClinical InterviewFull psychotic disorderDeficitsSpecific subdomainsSRGPPsychotic disordersPsychosisGesturesComparing a Computerized Digit Symbol Test to a Pen-and-Paper Classic
Pratt D, Luther L, Kinney K, Osborne K, Corlett P, Powers A, Woods S, Gold J, Schiffman J, Ellman L, Strauss G, Walker E, Zinbarg R, Waltz J, Silverstein S, Mittal V. Comparing a Computerized Digit Symbol Test to a Pen-and-Paper Classic. Schizophrenia Bulletin Open 2023, 4: sgad027. PMID: 37868160, PMCID: PMC10590153, DOI: 10.1093/schizbullopen/sgad027.Peer-Reviewed Original ResearchClinical high riskCHR individualsFinger-tapping taskMotor ability measuresDigit symbol testCHR stateHealthy controlsHigh riskClinical InterviewPersistent subgroupSymbol testPersistent groupImpairmentPaper versionMotor abilitiesTask performance differencesComputerized versionSimilar degreeEffect sizeMeasures impairmentPsychosisCoding TestRemote assessmentSubgroupsDigit-symbol task
2022
Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis
Williams TF, Powers AR, Ellman LM, Corlett PR, Strauss GP, Schiffman J, Waltz JA, Silverstein SM, Woods SW, Walker EF, Gold JM, Mittal VA. Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis. Schizophrenia Research 2022, 244: 58-65. PMID: 35597134, PMCID: PMC9829103, DOI: 10.1016/j.schres.2022.05.006.Peer-Reviewed Original ResearchConceptsProdromal Questionnaire-BriefPositive symptomsSelf-report questionnairesSpecific positive symptomsStructured Clinical InterviewClinical high riskCriterion validityHealthy controlsSpecific symptomsHigh riskDiscriminant validityPsychosis symptomsClinical InterviewCHR individualsStrong convergent validitySymptomsPsychosis riskNeuropsychological testsConsistent significant correlationLimited specificitySignificant correlationConvergent validityPsychosisConstruct validityQuestionnaire
2020
Modeling perception and behavior in individuals at clinical high risk for psychosis: Support for the predictive processing framework
Kafadar E, Mittal VA, Strauss GP, Chapman HC, Ellman LM, Bansal S, Gold JM, Alderson-Day B, Evans S, Moffatt J, Silverstein SM, Walker EF, Woods SW, Corlett PR, Powers AR. Modeling perception and behavior in individuals at clinical high risk for psychosis: Support for the predictive processing framework. Schizophrenia Research 2020, 226: 167-175. PMID: 32593735, PMCID: PMC7774587, DOI: 10.1016/j.schres.2020.04.017.Peer-Reviewed Original ResearchConceptsClinical high riskCHR participantsDegraded speech stimuliPredictive processing frameworkUtility of interventionsSample of participantsPerceptual inferenceSensory evidencePsychotic spectrum disordersSpeech stimuliSpeech taskComputational underpinningsBehavioral tasksEfficacy of interventionsSpectrum disorderTarget tonesParticipants' performanceComputational modelingHigh riskPoor recognitionLatent factorsSuch tasksPrior beliefsTaskAppropriate risk stratification
2019
Predictive validity of conversion from the clinical high risk syndrome to frank psychosis
Yoviene Sykes LA, Ferrara M, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Mathalon DH, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH, Woodberry KA, Powers AR, Ponce AN, Cahill JD, Pollard JM, Srihari VH, Woods SW. Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. Schizophrenia Research 2019, 216: 184-191. PMID: 31864837, PMCID: PMC7239715, DOI: 10.1016/j.schres.2019.12.002.Peer-Reviewed Original ResearchConceptsFrank psychosisFirst-episode psychosis patientsOne-yearNorth American Prodromal Longitudinal StudySeverity of illnessClinical high-risk syndromeCurrent antipsychotic medicationsHigh-risk syndromePsychosis risk syndromeClinical high riskPredictive validityFEP casesPrescription ratesAntipsychotic medicationPsychosis patientsRisk syndromePsychosis onsetHigh riskLittle investigative attentionDiagnostic stabilityCHR individualsPsychosis paradigmPsychosisLongitudinal studySyndrome
2017
Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups
Woods SW, Powers AR, Taylor JH, Davidson CA, Johannesen JK, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. Schizophrenia Bulletin 2017, 44: 254-263. PMID: 29036402, PMCID: PMC5814797, DOI: 10.1093/schbul/sbx138.Peer-Reviewed Original ResearchConceptsCHR syndromeDiagnostic outcomesCHR subgroupsClinical high-risk syndromeHigh-risk syndromeOnset of psychosisClinical high riskPersistence of anxietyEmergent psychosisCHR patientsRisk syndromeObservational studyCHR casesHigh riskNonpsychotic disordersComorbid disordersComparison subjectsBipolar disorderDiagnostic InterviewSyndromeDSM-IVPatientsPsychosisDiagnostic specificityComparison group